# Title: Microbially-derived indole-3-acetate alleviates diet induced steatosis and inflammation in mice

Yufang Ding[1], Karin Yanagi[2], Fang Yang[1], Evelyn Callaway[1], Clint Cheng[1], Martha E Hensel[3], Rani Menon[1], Robert C. Alaniz[4], Kyongbum Lee[2*], Arul Jayaraman[1,4*]

[1] Artie McFerrin Department of Chemical Engineering, Texas A&M University; College Station, TX 77843, USA

[2]Department of Chemical and Biological Engineering, Tufts University; Medford, MA 02155, USA

[3]Department of Pathobiology, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University; College Station, TX, USA

[4] Department of Microbial Pathogenesis and Immunology, College of Medicine, Texas Health Science Center, Texas A&M University; Bryan, TX, USA

*Corresponding author. Kyongbum.Lee@tufts.edu, arulj@tamu.edu

**Abstract:** Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in Western countries. There is growing evidence that dysbiosis of the intestinal microbiota and disruption of microbiota-host interactions contribute to the pathology of NAFLD. We previously demonstrated that gut microbiota derived tryptophan metabolite indole-3-acetate (I3A) was decreased in both cecum and liver of high-fat diet-fed mice and attenuated the expression of inflammatory cytokines in macrophages and TNF-a and fatty acid induced inflammatory responses in an aryl-hydrocarbon receptor (AhR) dependent manner in hepatocytes. In this study, we investigated the effect of orally administered I3A in a mouse model of diet induced NAFLD. Western diet (WD)-fed mice given sugar water (SW) with I3A showed dramatically decreased serum ALT, hepatic TG, liver steatosis, hepatocyte ballooning, lobular inflammation, and hepatic production of inflammatory cytokines, compared to WD-fed mice given only SW. Metagenomic analysis show that I3A administration did not significantly modify the intestinal microbiome, suggesting that I3A's beneficial effects likely reflect the metabolite's direct actions on the liver. Administration of I3A partially reversed WD induced alterations of liver metabolome and proteome, notably, decreasing expression of several enzymes in hepatic lipogenesis and β-oxidation. Mechanistically, we also show that AMP-activated protein kinase (AMPK) mediates the anti-inflammatory effects of I3A in macrophages. The potency of I3A in alleviating liver steatosis and inflammation clearly demonstrates its potential as a therapeutic modality for preventing the progression of steatosis to NASH.

## INTRODUCTION

Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in Western countries, with a prevalence rate of 21-25% in North American and Europe [1]. It is a multi-stage disease [2] that can progress from liver steatosis (characterized by macrovesicular fat deposition), which is benign and reversible [2,3], to more severe forms of the disease such as non-alcoholic steatohepatitis (NASH) and fibrosis. Approximately 25% of individuals having liver steatosis develop NASH, which is characterized by liver inflammation, dysregulated lipid metabolism, and cell damage [3]. A subset of NASH patients develops cirrhosis and even hepatocellular carcinoma [4]. Although significant progress has been made in understanding the pathogenesis of NAFLD, factors leading to the progression from steatosis to NASH remain poorly understood, and there are currently no pharmacological treatments available for NASH.

There is growing evidence that dysbiosis of the intestinal microbiota and disruption of microbiota-host interactions contribute to the pathology of NASH [5-8]. Certain shifts in the intestinal microbiota community composition, e.g., expansion of the phyla *Verrucomicrobia* and *Proteobacteria,* correlate with NASH in both human and animal studies [9,10]. One potential mechanism linking intestinal microbiota dysbiosis and NASH is compromised intestinal barrier integrity, which promotes the translocation of bacterial products from the lumen to circulation. This can contribute directly and indirectly (through intestinal inflammation) to liver inflammation [11-13]. Additionally, microbial dysbiosis alters the balance of bioactive metabolites produced by gut bacteria such as bile acids, short chain fatty acids and aromatic amino acid derivatives, which have been shown to impact liver metabolism and inflammation in NAFLD through host receptor mediated pathways [13].

In our previous study [14], we demonstrated that gut microbiota derived tryptophan metabolites indole-3-acetate (I3A) and tryptamine (TA) were decreased in both cecum and liver of high-fat

diet (HFD)-fed mice compared to low-fat diet (LFD)-fed control mice. *In vitro*, both I3A and TA attenuated the expression of inflammatory cytokines (*Tnfα*, *Il-1β* and *Mcp-1*) in macrophages exposed to palmitate and LPS. In hepatocytes, I3A significantly attenuated TNF-α and fatty acid induced inflammatory responses in an aryl-hydrocarbon receptor (AhR) dependent manner. Based on these findings, we hypothesized that I3A could protect against NAFLD progression *in vivo*. We show that supplementation of I3A in drinking water alleviates liver steatosis and inflammation even when mice are continued on the NAFLD inducing diet, and that these effects correlate with a decrease in both lipogenesis and β-oxidation in the liver. We also demonstrate that the anti-inflammatory effects of I3A in macrophages can be mediated by AMP-activated protein kinase (AMPK).

## RESULTS

### Oral administration of I3A alleviates diet induced hepatic steatosis and inflammation

We utilized a mouse model of diet-induced fatty liver disease [15] to investigate the effect of I3A administration through drinking water (Fig. S1A) on liver steatosis and inflammation. Similar to our previous finding in HFD fed mice [14], the levels of I3A were significantly reduced in fecal material (50% and 64% decrease at week 8 and 16, respectively) and the liver (70% decrease at week 16) of Western diet (WD) fed mice compared to control mice (CN) fed a low-fat diet. Mice that were given WD and sugar water (SW) containing I3A showed increased I3A levels in fecal material, the liver and serum compared to mice given the same WD and SW without I3A (Fig. S1A and 1B, Fig. S1C). Next, we sought to determine if the I3A administration impacted WD induced features of NAFLD. Compared to CN, WD fed mice had elevated serum alanine aminotransferase (ALT) levels, indicating liver injury. Treatment of WD fed mice with the high dose of I3A (WD-100) significantly reduced serum ALT levels two weeks after beginning the I3A treatment (week 10 time point, Fig. 1C) and beyond. Additionally, I3A treatment reduced liver TG in a dose-dependent manner at week 16 (Fig. 1D). Scoring of H&E-stained liver sections indicated that the I3A treatment improved liver steatosis, hepatocyte ballooning, and lobular inflammation in a dose-dependent manner (Fig. 1E and F). Treatment with I3A didn't alter weight increase nor food intake compared to WD fed mice (Fig. S1D).

We also investigated whether I3A treatment modulated the levels of inflammatory cytokines in WD-fed mice. All pro-inflammatory cytokines in the panel (e.g., *Tnfα*, *Il-6, Mcp-1*) were significantly elevated in livers of WD mice compared to CN (Fig. 2A and Fig. S2A). Treatment with I3A reduced the expression of these cytokines in a dose-dependent manner. Interestingly, WD upregulated IL-10, considered an anti-inflammatory cytokine, and I3A treatment downregulated this cytokine (Fig. S2A). Taken together, these results demonstrate that I3A, provided via drinking water, attenuates diet-induced hepatic steatosis, cellular injury, and inflammation in mice.

### I3A reverses diet induced alterations in liver bile acids and free fatty acids

Studies in mice and humans showed that NAFLD is associated with alterations in liver bile acids. Previously, we found that the ratio of chenodeoxycholic acid (CDCA) to cholic acid (CD) greatly decreased when HepG12 and AML12 cells were treated with I3A, indicating that I3A can directly alter host cell bile acid metabolism *in vitro* [14]. In the present study, mice in the WD group showed reduced liver total bile acids and CDCA-derived bile acids compared to CN (Fig. 2B). Treatment with I3A led to a further decrease in the CDCA-derived bile acids, consistent with our previous observation of I3A's effect on hepatocytes *in vitro*. We also measured the

concentrations of nine major free fatty acids (FFAs, Table S2). In the liver, WD significantly increased the total concentration of these FFAs by 2.7-fold compared to CN (Fig. S2B). Treatment with I3A had no significant effect, although the total FFA concentration trended lower in the WD-100 group (36% reduction, $p = 0.11$, Fig. S2B). The total FFA concentrations in serum were similar across all four groups (Fig. S2B).

**I3A administration does not significantly alter the fecal microbial community as well as fecal metabolome**

Next, we investigated whether the hepatoprotective effects of I3A were due to a modification of the gut microbiome. The fecal microbial communities at week 8 of WD (prior to I3A treatment) and week 16 (at termination) were analyzed using 16S rRNA sequencing. Fecal microbiome of WD fed mice showed reduced α-diversity compared to CN, which was not further altered upon I3A treatment (Fig. S3A). Similarity analysis using the Bray-Curtis dissimilarity metric showed that the microbiome compositions of CN and WD-fed mice were significantly different (Fig. S3B). The fecal microbiome compositions of WD-fed mice did not change significantly upon I3A treatment (Fig. S3B). Analysis of fecal microbiota taxonomic profiles at the phylum and genus level (Fig. S3C and S3D) showed major shifts in bacterial abundance of fecal microbiota from WD-fed mice relative to CN. At week 16, the relative abundance of phylum *Verrucomicrobia* increased, whereas *Bacteroidetes* decreased. LEfSe detected 18 taxa showing significant differences in relative abundance between the WD group and CN, including an expansion of the genus *Akkermansia* and reduction of family *Muribaculaceae*. In contrast, only 3 genera showed significant shifts in WD fed mice upon I3A treatment (Fig. S3E).

We also investigated whether administration of I3A altered the metabolic profile of the gut microbiota. Principal component analysis (PCA) of untargeted LC-MS data showed that the fecal metabolome of WD fed mice was significantly different from CN, whereas the metabolomes of WD-100 and WD groups largely overlapped (Fig. S4A). Although permutational multivariate analysis of variance (PERMANOVA) suggested a modest difference in the variance of metabolite levels between WD-50 and WD groups, Hotelling's $T^2$ test found that the means (centroids) were not significantly different. Clustering analysis using the k-means showed that fecal metabolites could be assigned into 4 groups (Fig. S4B). We did not observe any clusters that showed a reversal of WD induced changes in fecal metabolome by I3A treatment. Taken together, these results indicate that treatment with I3A had minimal effects on the fecal microbiota composition and metabolome of WD fed mice.

**High-dose I3A administration partially reverses diet induced metabolome alterations in the liver**

We next investigated the impact of I3A treatment on the liver metabolome using untargeted LC-MS. Projections of all annotated features onto latent variables from PLS-DA showed that the liver metabolome of WD-fed mice was significantly different from CN (Fig. 3A). The low dose I3A (WD-50) group completely overlapped with the WD group, whereas the high dose (WD-100) group was significantly different from both WD and CN groups (Fig. 3A). To further determine if the high dose of I3A was able to reverse the diet-induced alterations in liver metabolome, we performed a clustering analysis on all 30 annotated features that were significantly (FDR<0.1) different in WD mice compared to CN. This analysis placed the significant features into 4 groups. Group 1 comprised metabolites that were further increased or depleted by the high dose of I3A, whereas groups 3 and 4 comprised metabolites having WD-

166 induced changes that were reversed by I3A treatment (except for vigabatrin) (Fig. 3B).
167 Enrichment analysis based on KEGG pathways (Fig. 3C) showed that nicotinate and
168 nicotinamide metabolism and steroid hormone biosynthesis were significantly altered by WD
169 (CN vs WD), which were reversed by the high dose I3A treatment (WD vs WD-100).

170 Because nicotinamide and nicotinate are products of tryptophan metabolism, we manually
171 integrated the peak areas for all features we identified as tryptophan metabolites (Fig. 3D). This
172 added formylkynurenine, kynurenic acid and xanthurenic acid to the list of annotated metabolites
173 comprising the kynurenine branch of tryptophan metabolism. The high dose of I3A restored
174 WD-induced depletion of metabolites in the upper kynurenine branch, and ameliorated WD-
175 induced increases in niacin and nicotinamide in the lower branch. These effects were dose-
176 dependent, as they were not present in the WD-50 group.

177 Acyl-carnitines comprise another class of metabolites having abundances that were returned to
178 CN levels in WD-fed mice by the high dose of I3A (Fig. 3E). Compared to CN, mice in the WD
179 group showed elevated levels of long-chain 3-hydroxylacyl-carnitines. These acyl-carnitines are
180 closely linked to 3-hydroxylacyl-CoAs, which are intermediates of beta-oxidation, and their
181 accumulations suggest incomplete beta-oxidation [16,17]. Treatment with the high dose of I3A
182 significantly reversed these accumulations. As was the case for tryptophan metabolites, the effect
183 of I3A on acyl-carnitines was dose-dependent.

184 **I3A administration partially reverses diet induced proteome alterations in the liver**

185 We next investigated if I3A also changed the expression levels of liver proteins altered by the
186 WD. Latent variable projections from PLS-DA on liver proteomics data (Fig. 4A) showed that
187 the WD group had a protein abundance profile significantly different from CN ($p < 10^{-6}$,
188 Hotelling's $T^2$). The effect of I3A was dose-dependent; whereas the WD-50 group was not
189 significantly different from the WD group, the WD-100 group was significantly different from
190 the WD group ($p < 0.001$). The PLS-DA projections for WD-100 were closer to CN than WD,
191 but still significantly different from CN. Principal component analysis (PCA) of the proteomics
192 data showed similar trends (Fig. S5).

193 Clustering and silhouette analysis on significant (differentially abundant) proteins with VIP
194 scores > 1.2 in the PLS-DA projections identified three clusters of proteins based on their
195 abundance profiles. Proteins in cluster 1 had lower abundance in the WD group compared to CN.
196 This trend was reversed in the WD-100 group (Fig. 4B). Proteins in cluster 2 had lower
197 abundance in the WD group compared to CN, but this trend was not reversed in the WD-100
198 group. Proteins in cluster 3 had higher abundance in the WD group compared to CN. These
199 proteins had similar abundance in the WD-100 group and CN. The protein abundance profiles
200 were similar between WD-50 and WD groups in all three clusters. These results suggest that the
201 I3A treatment partially reversed the diet-induced alterations in the liver proteome in a dose-
202 dependent manner, similar to the trend observed for the liver metabolome.

203 We performed an enrichment analysis to identify liver biochemical pathways significantly
204 altered by diet and I3A treatment. In total, 454 quantified proteins were associated with 276
205 KEGG pathways. Of these, 22 proteins were differentially abundant in WD mice compared to
206 CN. These proteins were associated with 6 significantly enriched pathways (Fig. 4C). A
207 comparison of the WD-100 and WD groups identified 52 differentially abundant proteins that
208 were associated with 5 significantly enriched pathways. One metabolic pathway, biosynthesis of
209 unsaturated fatty acids, was common to both sets of enriched pathways.

210 We used targeted proteomics to quantify fatty acid metabolism enzymes identified in the
211 untargeted proteomics data (Fig. 5). Platelet glycoprotein 4 (CD36), a major fatty acid uptake
212 protein, was elevated in the WD group compared to CN. The abundance of CD36 was decreased,
213 but not significantly, in the WD-100 group compared to WD (Fig. 5A). The abundance of fatty
214 acid synthase (Fasn) was not significantly different between the WD group and CN but was
215 decreased in the WD-100 group compared to the WD group (Fig. 5A). Acetyl-CoA carboxylase-
216 2 (Acab), which regulates mitochondrial β-oxidation, was decreased in the WD group compared
217 to CN, but was not significantly different between the WD-100 group compared to WD (Fig.
218 5B). Enzymes catalyzing mitochondrial β-oxidation, including long-chain acyl-CoA
219 dehydrogenase (Acadl), medium-chain acyl-CoA dehydrogenase (Acadm), short-chain acyl-CoA
220 dehydrogenase (Acads) and hydroxyacyl-CoA dehydrogenase (Hadh) trended higher in the WD
221 group compared to CN, although only Hadh showed a statistically significant difference (Fig.
222 5B). All four enzymes were significantly decreased in the WD-100 group compared to WD. A
223 similar trend was observed for peroxisomal β-oxidation enzymes acyl-CoA oxidase 1 (Acox1)
224 and peroxisomal 3-ketoacyl-CoA thiolases (Acaa1a and Acaa1b, Fig. 5C). These results suggest
225 that WD feeding led to increased cellular uptake, transport into mitochondria, and β-oxidation of
226 fatty acids, while administration of I3A reduced fatty acid synthesis and β-oxidation. As β-
227 oxidation generates reactive oxygen species (ROS), we also performed a targeted analysis of two
228 antioxidant enzymes detected by the untargeted proteomics experiments, catalase (CatB) and
229 glutathione peroxidase 1 (Gpx1), and administration of I3A reduced the levels of both enzymes
230 compared to WD (Fig. S6A). Previous *in vitro* studies in hepatocytes have shown that AhR
231 activation upregulates hepcidin (Hamp) [18,19], a secreted liver protein that regulates iron
232 absorption. Mice fed the WD showed significantly reduced Hamp abundance in the liver, which
233 was dose-dependently increased by I3A treatment (Fig. S6B). Another iron carrier protein,
234 serotransferrin, showed an opposite trend; its abundance significantly increased in the WD group
235 compared to CN, and dose-dependently decreased by I3A treatment (Fig. S6B).

236 **I3A suppresses macrophage inflammation in an AMPK but not AhR dependent manner**

237 Since our previous study found that the metabolic effects of I3A in hepatocytes depend on the
238 AhR, we tested if this was also the case in macrophages. The expression of AhR in RAW 264.7
239 macrophages is very low compared to murine AML12 hepatocytes (Fig. S7A). Treatment with
240 AhR inhibitor CH223191 did not alter I3A's effect on reducing palmitate and LPS induced *Tnfα*
241 and *Il-β* expression in RAW 264.7 macrophages (Fig. S7B and S7C), indicating that the anti-
242 inflammatory effect of I3A in macrophages likely does not require AhR activity.

243 Given that AMPK is a well-known signaling mediator in lipid metabolism and inflammation [20-
244 22], and has been shown to play a role in the progression of NAFLD [23,24], we investigated if the
245 levels of AMPK and p-AMPK were altered in the different treatment groups. Both p-AMPK and
246 AMPK were significantly downregulated in livers of the WD group compared to CN (Fig. 6A).
247 Administration of I3A reversed this effect in a dose-dependent manner and increased both
248 AMPK as well as p-AMPK (Fig. 6B).

249 We tested the role of AMPK in RAW 264.7 macrophages *in vitro*. Palmitate and LPS treatment
250 significantly reduced p-AMPK levels by 50% compared to vehicle control but did not affect total
251 AMPK (Fig. 6C and 6D). Treatment with I3A upregulated p-AMPK to baseline levels without
252 altering total AMPK (Fig. 6C and 6D). Palmitate and LPS also led to an increase in *Tnfα* and *Il-*
253 *1β* expression (Fig. 6E), while activation of AMPK with AICAR attenuated the palmitate and
254 LPS stimulated increase in *Tnfα* and *Il-1β* expression by 30% and 80%, respectively (Fig. 6E).

255 These results suggest that upregulation of p-AMPK modulates the expression of *Tnfα* and *Il-1β*
256 in RAW 264.7 macrophages.

257 We next investigated if the anti-inflammatory effect of I3A in RAW macrophages that we
258 previously reported [14] depends on AMPK activation. We used siRNA to knock down prkaa1, the
259 gene encoding AMPKα1, the main form of AMPKα in murine macrophages [25], and measured its
260 effect on pro-inflammatory cytokine expression. The knockdown efficiency was ~50% for
261 mRNA (Fig. S8A), ~ 40-50% for AMPK protein, and ~50 – 60% for p-AMPK (Figs. S8B and
262 S8C), and the knockdown was stable for up to 96 h at both mRNA and protein levels. In cells
263 transfected with the non-targeted control siRNA (Fig. 6F left panel), palmitate and LPS
264 increased tnfα and il-1β expression by ~10- and 250-fold, respectively (Fig. 6F), and I3A
265 significantly downregulated this by ~30% and 50% for *Tnfα* and *Il-1β*, respectively, relative to
266 the DMF control. In contrast, I3A did not significantly modulate *Tnfα* expression in prkaa1
267 siRNA transfected cells stimulated with palmitate and LPS, and only reduced *Il-1β* expression by
268 ~20 % (Fig. 6F) relative to the DMF control. These results suggest that I3A's anti-inflammatory
269 effect in RAW 264.7 macrophages depend on AMPK activation.

270 **DISCUSSION**

271 Based on our previous finding that I3A modulates inflammatory cytokine expression in
272 macrophages and fatty acid metabolism in hepatocytes [14], we hypothesized that I3A could
273 mitigate liver steatosis and other NAFLD features *in vivo*. Using a mouse model of WD-induced
274 NAFLD [15], we show that oral administration of I3A protects against liver injury in a dose-
275 dependent manner (Fig. 1C), attenuates liver TG accumulation (Fig. 1D), and reduces steatosis,
276 hepatocyte ballooning, and lobular inflammation (Figs. 1E and 1F), suggesting that
277 administration of I3A altered both metabolic and inflammation pathways in the liver. As
278 expected, WD induced significant additional weight gain. Treatment with I3A had negligible
279 impact on the weight gain and did not reduce food intake.

280 Production of pro-inflammatory cytokines such as TNFα, IL-1β, MCP-1 and IL-6 by resident
281 macrophages (Kupffer cells) signals recruitment and infiltration of monocytes into the liver.
282 These cytokines also promote the differentiation of monocytes into pro-inflammatory
283 macrophages, which in turn exacerbates dysregulation of hepatic lipid metabolism [26,27].
284 Consistent with the lobular inflammation score, there was a significant increase in the expression
285 of inflammatory cytokines in livers of the WD group (Fig. 2A). Remarkably, treatment of WD
286 fed mice with I3A dose-dependently reduced the expression of every cytokine in the 13-member
287 panel, including IL-10. The downregulation of IL-10 in I3A treated mice could be a result of
288 reduced hepatic inflammation (i.e., feedback regulation of IL-10 production). Whether the
289 decrease in inflammatory cytokine production is due to I3A's anti-inflammatory effects in liver
290 immune cells [14] or due to modulation of lipid metabolism in hepatocytes warrants further
291 investigation.

292 Studies have shown that the alteration of bile acid metabolism could be a biomarker for NAFLD
293 [28]. Mice in the WD group had a lower total concentration of liver bile acids and higher
294 proportion of primary bile acids compared to CN (Fig. 2B). The latter trend is consistent with
295 previous studies comparing bile acid profiles between NASH patients and healthy controls [29].
296 Compared to our previous *in vitro* results, the effect of I3A treatment on liver bile acids was
297 modest, possibly due to regulatory mechanisms present *in vivo*. Moreover, CDCA is metabolized
298 into muricholic acids in mice which are absent in humans and have different affinities for bile

acid receptors compared to CDCA and lithocholic acid, a CDCA-derived secondary bile acid. Knockout mouse models that lack the bile acid metabolizing enzymes Cyp2c70/Cyp2a12 have bile acid pools closer to humans [30,31]. Future studies utilizing these models could help elucidate the physiological impact of I3A on liver bile acids and their role in fatty liver disease.

The observation that the fecal microbial community composition was not significantly altered by I3A administration suggests that the hepatoprotective effects of I3A are likely due to the metabolite's direct action on the host, rather than the gut microbiota composition. One caveat to this interpretation is the shallow resolution of 16S rRNA sequencing. It is possible that I3A administration altered the microbiota composition at the species level. It is also possible that I3A could affect the metabolism of the microbiota without altering its composition. A recent study [32] showed that a diet containing high levels of methionine and cysteine protected mice against chronic kidney disease by reducing uremic toxins through post-translational modification of gut bacterial enzymes. To test the possibility that I3A administration altered the intestinal metabolome, we performed untargeted metabolomics experiments on fecal samples. The results showed no significant impact of I3A on the fecal metabolomes of WD mice. While further studies are warranted to fully elucidate the impact of I3A administration on the microbiome and microbial gene expression in the intestine, these results suggest that the partial reversal of WD-induced changes in liver metabolome and proteome by I3A treatment is due to the metabolite's direct action on the liver.

Analysis of enzymes in lipid transport, synthesis, and mobilization showed that WD and I3A impacted different facets of lipid metabolism. Targeted proteomics detected a 6- fold increase in fatty acid translocase CD36 in the WD group compared to CN, suggesting that the elevation of liver FFAs in the WD group (Fig. S2B) could be due to increased uptake. I3A did not affect CD36 abundance, but significantly decreased Fasn by 86%, the rate limiting enzyme in *de novo* lipogenesis. This suggests that the significant decrease in liver TG in the WD-100 group could reflect a downregulation of *de novo* lipid synthesis in the liver.

Liver fatty acid oxidation (FAO) enzymes also showed different responses to WD and I3A. Acetyl-CoA carboxylase 2 (Acab) is a mitochondrial regulatory enzyme that produces malonyl-CoA, which inhibits carnitine palmitoyltransferase 1 (CPT1) [33]. Downregulation of Acab in the WD group compared to CN suggests increased CPT1 activity and hence elevated long-chain FA (LCFA) transport into the mitochondria [34]. This interpretation is also supported by the observation that long-chain 3-hydoxy-acyl carnitines were elevated in the WD group compared to CN, which is consistent with a recent study reporting elevated serum C14 hydroxy-acylcarnitine in NAFLD patients [35]. Other mitochondrial fatty acid oxidation (FAO) enzymes also showed a trend towards upregulation in the WD group compared to CN. Upregulation of FAO by WD was significant in the peroxisomes, the initial site of very long-chain FA oxidation. The literature is conflicted on FAO in human subjects with NAFLD or NASH. Depending on the study, enhanced [36-38], unchanged [39,40] or decreased [41] FAO has been reported. The different results may reflect varying severity of the disease (degree of steatosis or steatosis vs. NASH) and variations in FAO capacity across individual subjects. One study [42] showed that the expression of genes in peroxisomal and mitochondria β-oxidation was higher in patients with more severe steatosis compared to patients with less sever steatosis or healthy control. Administration of I3A significantly reduced the abundance of both mitochondrial and peroxisomal FAO enzymes. Increased FAO and concomitant ROS generation can overwhelm cellular antioxidant defenses, inducing oxidative stress. Although there is a lack of consensus regarding FAO, studies

344 consistently report elevated markers of oxidative stress in human subjects with steatosis [43-45]. In
345 this regard, I3A may protect from oxidative stress by reducing FAO. This is consistent with our
346 observations that I3A administration reversed the WD-induced accumulation of long-chain 3-
347 hydroxy-acylcarnitines and that the changes in abundance of FAO enzymes were upstream of 3-
348 hydroxy-acyl-CoAs. Oxidative stress induced enzymes CAT and GPx were upregulated in the
349 WD group compared to CN and downregulated in the WD-100 group compared to the WD
350 group. It should be noted that all the biochemical parameters related to lipid metabolism were
351 assessed at termination of the mouse experiments. It is possible that the downregulation of FAO
352 enzymes in I3A treated mice reflects a response to reduced lipid accumulation. Further
353 longitudinal studies are warranted to determine the (likely) dynamic effects of I3A on the liver
354 lipid metabolism.

355 Recent studies have demonstrated that tryptophan derived gut bacterial metabolites, including
356 I3A, are AhR agonists in intestinal epithelial cells [46] hepatocytes [14] and immune cells [28]. In our
357 previous study [14], we observed that I3A decreased the expression of Fasn and its transcriptional
358 regulator SREBP-1c in hepatocytes in an AhR dependent manner. In the current study, we again
359 found that Fasn was downregulated by I3A treatment. Additionally, we observed a dose-
360 dependent upregulation of hepcidin in mice treated with I3A. Previously, tryptophan derived
361 metabolites indoxyl sulfate and kynurenine have been shown to induce hepcidin expression in
362 HepG2 cells in an AhR-dependent manner [18,19]. Hamp is a master regulator of systemic iron
363 homeostasis that binds to ferroportin and inhibits the absorption of dietary iron and efflux of iron
364 from liver resident macrophages. Iron overload is common among NAFLD patients [47], and the
365 excess iron along with inflammation can induce hepcidin in these patients [48-51]. However,
366 hepcidin gene expression decreases when NAFLD progresses to NASH [51], suggesting that
367 disease progression is linked to impaired regulation of iron metabolism. Hepcidin knockout in a
368 mouse model of NAFLD ameliorated steatosis while exacerbating fibrosis [52]. In contrast,
369 hepcidin overexpression decreased choline-deficient diet induced steatosis, inflammation and
370 fibrosis in a mouse model of NASH [53]. Whether I3A induction of hepcidin ameliorates iron
371 overload and how this could contribute to I3A's protective role needs to be investigated.

372 Another set of WD-induced metabolic alterations that were reversed by I3A treatment and likely
373 mediated through the AhR are restorations of tryptophan metabolite levels. Studies in
374 hepatocytes have shown that AhR knockdown down-regulates tryptophan 2,3-dioxygenase,
375 kynurenine 3-monooxygenase, and kynureninase, enzymes that direct flux into the kynurenine
376 branch of tryptophan metabolism. Another study reported that kynurenine activation of the AhR
377 upregulated expression of indoleamine 2,3-dioxygenase 2 in dendritic cells [54]. In the present
378 study, I3A treatment of WD-fed mice directed flux of tryptophan into kynurenic, anthranilic, and
379 xanthurenic acids, reducing flux towards niacin and nicotinamide. Given that kynurenine,
380 kynurenic acid, anthranilic acid, and xanthurenic acid are all AhR agonists, this could have
381 further enhanced AhR activation by I3A treatment.

382 In macrophages, however, I3A's effects were independent of AhR activity, as addition of the
383 AhR inhibitor did not alter the effects (Fig. S7). Studies in HFD-fed mice showed dysregulation
384 of liver AMPK activity and its association with increased lipid accumulation [20,21,55]. *In vitro*, LPS
385 activated macrophage showed upregulation of heme oxygenase-1 (HO-1), an AMPK regulated
386 protein, upon I3A exposure [56]. Based on these reports, we investigated if AMPK was involved in
387 mediating the response to I3A. We show that both liver AMPK expression and phosphorylation
388 were reduced in WD-fed mice relative to CN, and that administration of I3A rescued both

389 AMPK expression and phosphorylation in a dose-dependent manner (Fig. 6). Using an *in vitro*
390 model, we demonstrate a similar AMPK dependence of I3A's anti-inflammatory effect in murine
391 macrophages (Fig. 6). Whether AMPK signaling plays a role in mediating I3A's effects in
392 hepatocytes *in vivo* and whether this is important relative to I3A's activation of the AhR warrants
393 further investigation.

394 In summary, we have shown that oral administration of a microbiota derived tryptophan
395 metabolite, I3A, in WD-fed mice alleviates diet-induced liver steatosis and inflammation, even
396 when the mice were continued on WD. These hepatoprotective effects occurred without
397 significant alterations in the gut microbiome composition and metabolome profiles, suggesting
398 that I3A acted directly on host cells. Untargeted LC-MS experiments showed activation of
399 several AhR-regulated pathways, suggesting that I3A's effects are partially mediated through
400 this nuclear receptor. Additionally, *in vivo* results show a correlation between AMPK
401 phosphorylation and the efficacy of I3A, while our *in vitro* studies with RAW macrophages
402 show that AMPK mediates I3A's attenuation of pro-inflammatory cytokine expression. While
403 our results do not rule out the involvement of additional signaling pathways in both hepatocytes
404 and macrophages, or interactions between the liver and other tissues (e.g., adipose tissue), the
405 data nevertheless strongly point to I3A directly modulating lipid metabolism and inflammatory
406 cytokine production in the liver.

407 Recently, several other studies reported on the protective effects of I3A in various mouse models
408 [57,58]. However, there are significant differences between the other studies and our work. The
409 prior studies modeled steatosis using short-term (less than 4 weeks) HFD exposure, whereas we
410 modeled the later stages of NAFLD (i.e., with steatosis and inflammation) utilizing long-term
411 (16 weeks) exposure to WD and sugar water. Moreover, in contrast to the other studies, I3A was
412 administered concurrently with WD and sugar water for the last eight weeks of the study.
413 Despite the differences in the study design, the common conclusion from the above studies and
414 our work is that I3A administration decreases hepatic TG. In addition, our study shows that
415 administration of I3A significantly decreases hepatic inflammation and lipid metabolism with
416 minimal modulation of the gut microbiome composition and metabolic function.
417 Mechanistically, we also show that I3A's anti-inflammatory effects in RAW 264.7 macrophages
418 are mediated through activation of AMPK, whereas its effects in hepatocytes are mediated
419 through the AhR [14]. Thus, demonstrating that I3A elicits protective effects in NAFLD through
420 two signaling pathways in different cell types is a novel and significant finding from our study.

421 Based on our data, we propose a model describing I3A's effects in the liver (Fig. S9). While
422 additional studies are warranted to investigate the above-mentioned possibilities, the remarkable
423 potency of I3A in alleviating steatosis and inflammation in a therapeutic model clearly
424 demonstrates the potential for developing I3A as an inherently safe treatment option for NAFLD.
425 To this end, preclinical studies should be conducted to evaluate delivery options such as
426 botanical extracts and probiotics, while human subject studies should be performed to determine
427 safety, tolerability, and side effects of I3A. Prospectively, other tryptophan derived microbiota
428 metabolites as well as diets that result in enhanced production of these metabolites in the GI tract
429 could also be investigated for protection against WD-induced hepatic steatosis and inflammation.

430 **MATERIALS AND METHODS**

431 **Study design**

432 The overall objective of the study was to investigate if I3A can alleviate diet induced liver steatosis
433 and inflammation *in vivo*. We induced these NAFLD features in mice by feeding the animals a
434 WD and SW for 8 weeks. The drinking water for these mice was then supplemented with low and
435 high doses of I3A, while continuing the WD for another 8 weeks. The phenotypic changes were
436 assessed by measuring body weight gain, serum ALT, hepatic inflammatory cytokines, and
437 histopathological examination of liver tissue. To investigate potential mechanisms of action, we
438 performed a series of omics analyses on fecal material (metagenomics and metabolomics) and
439 liver tissue (metabolomics and proteomics). To determine cell-type specific signaling mediating
440 I3A effects in macrophages, we used an *in vitro* cell culture model. The histopathological scoring
441 of liver sections was blinded; all other analyses were not blinded. Sample processing and statistical
442 analysis were performed concurrently on treatment and control groups using identical methods.
443 Numbers of replicates and outcomes of statistical tests are indicated in the figure legends.

444 **Materials**

445 RAW 264.7 cells were purchased from ATCC (Manassas, MA). Dulbecco's Modified Eagle
446 Medium (DMEM), penicillin/streptomycin, and LPS (from *Salmonella minnesota*) were
447 purchased from Invitrogen (Carlsbad, CA). Fetal bovine serum (FBS) was purchased from
448 Atlanta Biologicals (Flowery Branch, GA). All free fatty acid chemicals, 5-aminoimidazole-4-
449 carboxamide ribonucleotide (AICAR) and the AhR inhibitor CH-223191 were purchased from
450 Millipore Sigma (St. Louis, MO). Indole-3-acetate sodium salt (I3A) was purchased from
451 Cayman chemicals (Ann Arbor, MI). All other chemicals were purchased from VWR (Radnor,
452 PA) or Millipore Sigma unless otherwise specified.

453 **Animal experiments**

454 Male B6 129SF1/J mice at 6 weeks of age were obtained from Jackson Laboratories (Bar
455 Harbor, ME). Mice were acclimatized to the animal facility for one week. At the start of the
456 experiment, mice were randomly divided into four groups (n=10 for each group). Three of the
457 four groups were fed *ad libitum* a Western diet (WD) with 40% Kcal from fat and containing
458 0.15% cholesterol (D12079B, Research Diets) and a sugar water (SW) solution (23.1g/L d-
459 fructose + 18.9g/L d-glucose) as previously described (DIAMOND model [15]). After 8 weeks, the
460 three groups of WD-fed mice were randomly selected for treatment with vehicle (WD group) or
461 low (WD-50 group) or high dose (WD-100 group) of I3A. The WD group was fed WD and
462 drank sugar water. The WD-50 and WD-100 groups were fed WD and drank sugar water
463 containing, respectively, 50 or 100 mg I3A per kg body weight. The treatments were continued
464 for another 8 weeks. Water bottles containing SW and I3A or only SW were changed every other
465 day. A fourth group of mice was fed a low-fat control diet (D12450B, Research Diets) and
466 normal water for 16 weeks (CN group) (Fig. S1A). Mice belonging to the same treatment group
467 were housed together (5 mice/cage). Mice were maintained on 12:12-h light-dark cycles. All
468 procedures were performed in accordance with Texas A&M University Health Sciences Center
469 Institutional Animal Care and Use Committee guidelines under an approved animal use protocol
470 (AUP #2017-0145).

471 **Sample collection**

472 Fecal pellets were collected every other week prior to I3A treatment, right before I3A treatment,
473 every week during I3A treatment, and on the last day of the experiments (Fig. S1B). All fecal
474 pellets were flash frozen in liquid nitrogen after collection. Blood samples from the
475 submandibular vein were taken right prior to I3A treatment, every other week during I3A

476 treatment and on the last day of the experiments. The blood samples were centrifuged at 4,000g
477 for 15 min at 4°C to obtain serum. At the end of the experiment, the mice were sacrificed by
478 euthanasia. The liver was quickly excised and rinsed with 10x volume of ice-cold PBS. The right
479 medium lobe of the liver was fixed in 10% neutral formalin for histological analysis. A small
480 piece from right lateral lobe was stored in RNAlater (Sigma Aldrich, St. Louis, MO) using the
481 manufacturer's protocol. The remaining liver tissue samples were flash frozen in liquid nitrogen,
482 homogenized in HPLC-grade water, lyophilized to a dry powder, and stored at -80°C until
483 further processing.

484 **Histological analysis**

485 Formalin fixed liver were embedded in paraffin, sectioned (5µm) and stained with hematoxylin
486 and eosin (H&E) through VWR histological services (Radnor, PA). Liver histology sections
487 were evaluated by an expert pathologist at Texas A&M University who was blinded to the
488 treatment conditions. Histology was assessed using the NASH CRN [59] and fatty liver inhibition
489 of progression (FLIP) consortia criteria [60].

490 **Serum ALT and hepatic TG measurement**

491 Alanine aminotransferase (ALT) was measured in serum samples using a commercial ELISA kit
492 (Cayman Chemical Company). Liver triglycerides (TG) were quantified using a commercial
493 colorimetric assay kit (Cayman Chemical Company). Briefly, lyophilized liver samples were
494 weighted and lysed in diluted NP-40 buffer. After centrifugation at 10,000g and 4°C for 15 min,
495 the supernatant was stored on ice for quantification of TG. A small amount of lyophilized liver
496 was used for DNA isolation using a DNA miniprep kit (Zymo Research, Irvine, CA). The TG
497 concentrations (mg/dl) were normalized to tissue DNA contents (µg).

498 **Fecal microbiome analysis**

499 Microbial DNA was extracted from homogenized fecal material using the Power soil DNA
500 extraction kit (Qiagen, Carlsbad, CA). The V4 region of 16S rRNA was sequenced on a MiSeq
501 Illumina platform [61] at the Microbial Analysis, Resources, and Services (MARS) core facility
502 (University of Connecticut). Illumina sequence reads were quality filtered, denoised, joined,
503 chimera filtered, aligned, and classified using mothur (v 1.40.4) following the Miseq SOP
504 pipeline. The SILVA database [62] was used for alignment and classification of the operational
505 taxonomic units (OTU) at 97% similarity. The taxonomic dissimilarities between different
506 treatment groups were calculated using the Bray-Curtis dissimilarity metric and visualized on
507 non-metric multidimensional scaling (NMDS) plots. Analysis of similarities (ANOSIM) was
508 used for statistical comparison of microbiome compositions between treatment groups.
509 The differential abundances of OTUs between two different groups were determined using
510 Linear discriminant analysis Effect Size (LEfSe) [63]. Fisher's index was calculated to estimate
511 the alpha diversity.

512 **Fecal and serum metabolite extraction**

513 Metabolites were extracted from fecal samples as described previously [64]. Briefly, fecal material
514 was weighed, homogenized, and extracted twice with chloroform/methanol/water. The aqueous
515 phase from the two extractions were combined, lyophilized, and stored at -80°C. Samples were
516 reconstituted in 100 µl methanol/water (1:1, v/v) prior to LC-MS analysis. Serum metabolites
517 were extracted with ice-cold methanol (1:4 serum:methanol). Samples were centrifuged twice at
518 15,000 x *g* for 5 min at 4°C. The supernatant was stored at -80°C until LC-MS analysis.

519 **Liver metabolite and protein extraction**

520 Lyophilized liver samples were weighted and homogenized using soft tissue homogenization
521 beads (Omni International) on a bead beater (VWR) with 1 ml ice- cold methanol/ water (91:9,
522 v/v). The samples were homogenized for one min, incubated on ice for 5 min, and centrifuged at
523 12,000 x *g* for 10 min at 4°C. The supernatant was transferred into a new sample tube through a
524 70 µm cell strainer. Ice-cold chloroform was added into the tube to obtain a final solvent ratio of
525 47.6/47.6/4.8 % methanol/chloroform/water [65]. After vigorous mixing, the samples were frozen
526 in liquid nitrogen and thawed at room temperature. The freeze-thaw cycle was carried out three
527 times. Samples were centrifuged at 15,000 x *g* for 5 min at 4°C. The supernatant and pellet were
528 each transferred into a new sample tube for metabolite and protein analysis, respectively.

529 For metabolite analysis, 1 ml of HPLC water was added to the supernatant and centrifuged at
530 10,000 x *g* for 5 min at 4°C to obtain phase separation. The upper and lower phases were
531 collected separately and filtered through 0.2 µm filters into new sample tubes. The filtered
532 samples were dried to pellets with a lyophilizer and stored at -80°C until further analysis. The
533 upper and lower phases were reconstituted in 100 µl methanol/water (1:1, v/v) and 200 µl
534 methanol, respectively, prior to LC-MS analysis. For protein analysis, the pellet was solubilized
535 in 650 µl extraction buffer (0.5% SDS, 1% v/v β-mercaptoethanol and 1M Tris-HCl, pH=7.6)
536 and 650 µl TRIzol reagent (Thermo Fisher Scientific, Waltham, MA) and incubated at 37°C for
537 one hour. The sample was centrifuged at 14,000 x *g* for 15 min at 4°C to obtain phase separation.
538 One ml of ice-cold acetone was mixed into the bottom protein layer. Following an overnight
539 incubation at -20°C, the samples were centrifuged at 14,000 x *g* for 15 min at 4°C. The
540 supernatant was discarded, and the pellet was washed 3× with 1 ml ethanol. The protein pellet
541 was then lyophilized and stored at -80°C until further analysis.

542 **Untargeted metabolomics**

543 Untargeted LC-MS experiments were performed on a Q Exactive Plus orbitrap mass
544 spectrometer (Thermo Fisher Scientific, Waltham, MA) coupled to a binary pump HPLC system
545 (UltiMate 3000, Thermo Fisher Scientific, Waltham, MA) at the Integrated Metabolomics
546 Analysis Core (IMAC) facility of Texas A&M university as previously described [64].
547 Chromatographic separation was achieved on a reverse phase (RP) column (Synergi Fusion 4µm,
548 150 mm x 2 mm, Phenomenex, Torrance, CA) using a gradient method (Table S3). Sample
549 acquisition was performed Xcalibur (Thermo Fisher Scientific, Waltham, MA). Raw data files
550 were processed in Compound Discoverer (version 3.0, Thermo Fisher Scientific, Waltham, MA).
551 Metabolite identification was performed by searching the features against mzCloud and
552 ChemSpider. For comparing the levels of metabolites between samples, the area under the curve
553 (AUC) determined in Compound Discoverer for each feature was normalized to the sum of the
554 AUCs for all features. If there're multiple features were annotated as the same metabolite, the
555 feature with highest confidence score and highest AUC was selected to represent the metabolite.

556 **Liver bile acid analysis**

557 Lyophilized liver samples were homogenized in 10 mM phosphate buffer at pH 6 (28 mg tissue
558 per ml buffer) on a bead beater (VWR, Radnor, PA) for 1 min. Samples were then centrifuged at
559 15,000 x *g* for 5 min at 4°C. The supernatant (200 µl) was mixed vigorously with 100 ng of d4-
560 glycohenodeoxycholic acid internal standard, 20 µl of saturated ammonium sulfate and 800µl of
561 acetonitrile, and then centrifuged at 15,000 x *g* for 5 min at 4°C. The supernatant was transferred
562 into a new sample tube and dried with a vacufuge (Eppendorf, Hauppauge, NY). Pellets were

563 resuspended in 100 µl methanol/water (1:1, v/v), vortexed for 30 sec, sonicated for 1 min, and
564 then centrifuged at 15,000 g and 4°C for 1 min. The supernatant was transferred into a new
565 sample tube and analyzed by LC-MS.

566 Targeted LC-MS experiments were performed on a TSQ Altis triple quadrupole mass
567 spectrometer (Thermo Fisher Scientific, Waltham, MA) coupled to a binary pump UHPLC
568 (Vanquish, Thermo Scientific) at the TAMU IMAC core facility. Chromatographic separation
569 was achieved on a Kinetex 2.6 µm, 100 mm x 2.1 mm polar C18 column (Phenomenex,
570 Torrance, CA) using a gradient method (Table S4). Scan parameters for target ions are listed in
571 Table S1. Sample acquisition and data analysis were performed with Trace Finder 4.1 (Thermo
572 Fisher Scientific, Waltham, MA). The calculated bile acid concentrations were normalized to the
573 level of spiked internal standard for each sample.

574 **Quantification of free fatty acids**

575 Serum and liver FFAs were analyzed using targeted LC-MS experiments performed on a
576 quadrupole-time of flight instrument (TripleTOF 5600+, AB Sciex, Framingham, MA) as
577 previously described [14] with minor modifications (Tables S2 and S5).

578 **Untargeted proteomics**

579 Proteins were reduced, alkylated, and digested into peptides using information dependent
580 acquisition (IDA) on a quadrupole-time of flight instrument (TripleTOF 5600+) as previously
581 described [66] with minor modifications (Supplemental Information, Table S6). Peptide ions
582 detected in the IDA experiment were annotated using ProteinPilot (v.5.0, AB Sciex) and further
583 processed using an inhouse script written in MATLAB to associate each protein identified in the
584 sample with a unique high-quality peptide (Fig. S9). The relative abundance of a protein was
585 determined by quantifying the corresponding peptide peak's AUC in Multi-Quant (v2.0, AB) and
586 normalizing the value by the sample's sum of all peptide AUCs.

587 **Targeted proteomics**

588 A panel of 15 proteins having differential abundance in the untargeted proteomics data were
589 selected for targeted measurements using product ion scans for representative peptides (Table
590 S7). The relative abundance of a target protein was determined by quantifying the corresponding
591 peptide peak's AUCs in MultiQuant and normalizing the value by the sample protein weight.

592 **Liver cytokine measurements**

593 Lyophilized liver samples were weighted and homogenized with 500 µl lysis buffer (50mM Tris,
594 150mM NaCl, 1% Triton X-100, 1mM EDTA and 1% protease inhibitor cocktail, PH=7.4) for 1
595 min on a bead beater (VWR, Radnor, PA). Samples were centrifuged at 20,000 x *g* for 15min at
596 4°C. The lipid layer was removed by pipetting and the supernatant was transferred into a new
597 tube. The centrifugation and lipid removal steps were repeated three times. The supernatant was
598 transferred into a new tube and the total protein concentration was measured with the BCA
599 protein assay (Thermo Fisher Scientific, Waltham, MA). A panel of 13 cytokines was quantified
600 with a bead-based ELISA kit (BioLegend, San Diego, CA) following the manufacturer's
601 protocol. Cytokine concentrations (pg/ml) were normalized to the corresponding sample total
602 protein concentration (mg protein/mg tissue).

603 **RAW 264.7 macrophage culture**

604 RAW 264.7 murine macrophages were cultured in a humidified incubator at 37°C and 5% $CO_2$
605 using DMEM supplemented with 10% heat inactivated FBS, penicillin (200 U/mL) and
606 streptomycin (200 µg/mL). Cells were passaged every 2-3 days and used within 10 passages
607 after thawing. For the two-hit model experiment, RAW 264.7 cells were seeded into 24-well
608 plates at a density of 2 x $10^5$ cells/ml and then treated with 1 mM I3A, followed by palmitate and
609 LPS as reported before [14]. For the p-AMPK activation experiment, RAW 264.7 cells were treated
610 with 1 mM AICAR for 4 h, followed by addition of 300 µM palmitate complexed with BSA.
611 Following an 18 h incubation, the cells were treated with 10 ng/ml LPS for another 6 hours.

612 **RNA extraction and qRT-PCR**

613 Total RNA was extracted from RAW 264.7 cell pellets using the EZNA Total RNA kit (Omega
614 Bio-Tek, Norcross, GA). Purity of isolated RNA was confirmed by A260/280 ratio. qRT-PCR
615 analysis was carried out using the qScript One-Step PCR kit (Quanta Biosciences, Gaithersburg,
616 MD) on a LightCycler 96 System (Roche, Indianapolis, IN). Fold-change values were calculated
617 using the $2^{-\Delta\Delta Ct}$ method, with β-actin as the housekeeping gene. The primer sequences are listed
618 in Table S8.

619 **AMPK Western blot analysis**

620 Cell pellets or lyophilized liver samples were lysed with modified RIPA buffer (50 mM Tris-
621 HCl, PH 7.4, 1% Triton X-100, 150 mM NaCl, 1 mM EDTA, and 0.5% Sodium deoxycholate)
622 supplemented with a protease inhibitor cocktail (Sigma), 10 mM NaF, and 1 mM $Na_3VO_4$. The
623 protein concentration was determined using the BCA protein assay kit (Pierce). Protein samples
624 were denatured with SDS and ~10 µg of protein was separated on a 10% SDS-PAGE gel.
625 Proteins were transferred to a PVDF membrane (Thermo Scientific, Waltham, MA) by wet-
626 transfer electrophoresis. Non-fat milk (5%) in TBST solution was used to block non-specific
627 binding. The blots were probed with appropriate primary antibodies (p-AMPK: 2535, total
628 AMPK: 2603, β-actin: 12620, Cell Signaling Technology) and secondary antibody (Anti-rabbit
629 horseradish peroxidase-conjugated secondary antibody, 7074, Cell Signaling Technology).
630 Proteins bound by both primary and secondary antibodies were visualized by chemiluminescence
631 after incubating the blot with Clarity Max Western ECL Blotting Substrate (Bio-Rad, Hercules,
632 CA). Blot images were acquired on a ChemiDoc gel imaging system (Bio-Rad, Hercules, CA).
633 Proteins were quantified by normalizing the intensity of the protein band of interest to the
634 intensity of the β-actin band in the same lane using the Image Lab software (Bio-Rad, Hercules,
635 CA).

636 **Small interfering RNA transfection**

637 Raw 264.7 cells were seeded into 6-well or 24-well plates at ~ 30% confluence and cultured for
638 24 h prior to transfection. Cells were transfected with ON-TARGETplus mouse prkaa1 siRNA
639 (Dharmacon, Lafayette, CO) or ON-TARGETplus non-targeting pool (negative control,
640 Dharmacon, Lafayette, CO) using the GenMute siRNA transfection reagent (SignaGen
641 Laboratories, Rockville, MD) according to manufacturer's instruction. After 24 h, the medium
642 was replaced with siRNA-free growth medium and incubated for an additional 24 to 72 h. The
643 transfection efficiency was determined by monitoring the AMPK mRNA and protein levels using
644 qRT-PCR and Western blot, respectively.

645 **Statistical analysis**

Determination of significant difference in the level of a metabolite between two experimental groups used the Student's t-test with FDR correction. KEGG pathway enrichment analysis of metabolomics data was performed using MetaboAnalyst 5.0 [67]. Principal component analysis (PCA) and PLS-DA of the metabolomics and proteomics data were conducted using the mixOmics R package (v6.10.9). Ellipses drawn to represent 95% confidence regions assumed Gaussian distribution of latent variables (for PLS-DA) or scores (for PCA). Significance of separation between treatment groups was determined by calculating a standardized Euclidean distance matrix on the coordinates of latent variables or scores and performing a pairwise permutational multivariate analysis of variance (PERMANOVA) with 999 permutations on the distance matrix [68] and Hotelling's T2 tests. A p-value of 0.05 was set as the significance threshold for all statistical comparisons. Heatmaps for liver metabolome (only significantly changed features), fecal metabolome and liver proteome were generated with auto-scaled data. The features were clustered using the k-means method with Pearson correlation as the similarity metric. For protein analysis, a Variable Importance in Projection (VIP) score was calculated for each protein based on the PLS-DA result, and proteins with a VIP score < 1.2 were excluded from the clustering analysis to avoid overfitting. KEGG pathway enrichment analysis of proteomics data was performed using clusterProfiler R package (3.14.3).

**List of Supplementary Materials**

Materials and Methods

Tables S1 to S8

Figures S1 to S10

**References and Notes**


1 Loomba, R. & Sanyal, A. J. The global NAFLD epidemic. *Nat Rev Gastroenterol Hepatol* **10**, 686-690 (2013). https://doi.org:10.1038/nrgastro.2013.171

2 Day, C. P. Non-alcoholic fatty liver disease: a massive problem. *Clinical medicine* **11**, 176-178 (2011).

3 Tiniakos, D. G., Vos, M. B. & Brunt, E. M. Nonalcoholic fatty liver disease: pathology and pathogenesis. *Annual review of pathology* **5**, 145-171 (2010). https://doi.org:10.1146/annurev-pathol-121808-102132

4 Calzadilla Bertot, L. & Adams, L. A. The Natural Course of Non-Alcoholic Fatty Liver Disease. *International journal of molecular sciences* **17** (2016). https://doi.org:10.3390/ijms17050774

5 Brandl, K. & Schnabl, B. Intestinal microbiota and nonalcoholic steatohepatitis. *Curr Opin Gastroenterol* **33**, 128-133 (2017). https://doi.org:10.1097/MOG.0000000000000349

6 Boursier, J. *et al.* The Severity of Nonalcoholic Fatty Liver Disease Is Associated With Gut Dysbiosis and Shift in the Metabolic Function of the Gut Microbiota. *Hepatology* **63**, 764-775 (2016). https://doi.org:10.1002/hep.28356

7 Loomba, R. *et al.* Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease. *Cell Metab* **25**, 1054-1062 e1055 (2017). https://doi.org:10.1016/j.cmet.2017.04.001

8 Aron-Wisnewsky, J. *et al.* Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. *Nat Rev Gastroenterol Hepatol* **17**, 279-297 (2020). https://doi.org:10.1038/s41575-020-0269-9

9 Hoyles, L. *et al.* Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women. *Nat Med* **24**, 1070-1080 (2018). https://doi.org:10.1038/s41591-018-0061-3

10 Le Roy, T. *et al.* Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. *Gut* **62**, 1787-1794 (2013). https://doi.org:10.1136/gutjnl-2012-303816

11 Saltzman, E. T., Palacios, T., Thomsen, M. & Vitetta, L. Intestinal Microbiome Shifts, Dysbiosis, Inflammation, and Non-alcoholic Fatty Liver Disease. *Front Microbiol* **9**, 61 (2018). https://doi.org:10.3389/fmicb.2018.00061

12 Bibbo, S. *et al.* Gut Microbiota as a Driver of Inflammation in Nonalcoholic Fatty Liver Disease. *Mediat Inflamm* (2018). https://doi.org:Artn 9321643
10.1155/2018/9321643

13 Ding, Y. *et al.* Interactions between gut microbiota and non-alcoholic liver disease: The role of microbiota-derived metabolites. *Pharmacol Res* **141**, 521-529 (2019). https://doi.org:10.1016/j.phrs.2019.01.029

14 Krishnan, S. *et al.* Gut Microbiota-Derived Tryptophan Metabolites Modulate Inflammatory Response in Hepatocytes and Macrophages. *Cell reports* **23**, 1099-1111 (2018). https://doi.org:10.1016/j.celrep.2018.03.109

15 Asgharpour, A. *et al.* A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer. *Journal of hepatology* **65**, 579-588 (2016). https://doi.org:10.1016/j.jhep.2016.05.005

16 Su, X., Han, X., Mancuso, D. J., Abendschein, D. R. & Gross, R. W. Accumulation of long-chain acylcarnitine and 3-hydroxy acylcarnitine molecular species in diabetic myocardium: identification of alterations in mitochondrial fatty acid processing in diabetic myocardium by shotgun lipidomics. *Biochemistry* **44**, 5234-5245 (2005). https://doi.org:10.1021/bi047773a

17 Natarajan, S. K. & Ibdah, J. A. Role of 3-Hydroxy Fatty Acid-Induced Hepatic Lipotoxicity in Acute Fatty Liver of Pregnancy. *International journal of molecular sciences* **19** (2018). https://doi.org:10.3390/ijms19010322

18 Hamano, H. *et al.* The uremic toxin indoxyl sulfate interferes with iron metabolism by regulating hepcidin in chronic kidney disease. *Nephrol Dial Transplant* **33**, 586-597 (2018). https://doi.org:10.1093/ndt/gfx252

19 Eleftheriadis, T., Pissas, G., Antoniadi, G., Liakopoulos, V. & Stefanidis, I. Kynurenine, by activating aryl hydrocarbon receptor, decreases erythropoietin and increases hepcidin production in HepG2 cells: A new mechanism for anemia of inflammation. *Exp Hematol* **44**, 60-67 e61 (2016). https://doi.org:10.1016/j.exphem.2015.08.010

20 Muse, E. D. *et al.* Role of resistin in diet-induced hepatic insulin resistance. *The Journal of clinical investigation* **114**, 232-239 (2004). https://doi.org:10.1172/JCI21270

21 Sag, D., Carling, D., Stout, R. D. & Suttles, J. Adenosine 5'-monophosphate-activated protein kinase promotes macrophage polarization to an anti-inflammatory functional phenotype. *Journal of immunology* **181**, 8633-8641 (2008).

22 Day, E. A., Ford, R. J. & Steinberg, G. R. AMPK as a Therapeutic Target for Treating Metabolic Diseases. *Trends Endocrinol Metab* **28**, 545-560 (2017). https://doi.org:10.1016/j.tem.2017.05.004

23 Smith, B. K. *et al.* Treatment of nonalcoholic fatty liver disease: role of AMPK. *American journal of physiology. Endocrinology and metabolism* **311**, E730-E740 (2016). https://doi.org:10.1152/ajpendo.00225.2016

24 Herzig, S. & Shaw, R. J. AMPK: guardian of metabolism and mitochondrial homeostasis. *Nat Rev Mol Cell Biol* **19**, 121-135 (2018). https://doi.org:10.1038/nrm.2017.95

25 Yang, Z., Kahn, B. B., Shi, H. & Xue, B. Z. Macrophage alpha1 AMP-activated protein kinase (alpha1AMPK) antagonizes fatty acid-induced inflammation through SIRT1. *J Biol Chem* **285**, 19051-19059 (2010). https://doi.org:10.1074/jbc.M110.123620

26 Seki, E. & Schwabe, R. F. Hepatic inflammation and fibrosis: functional links and key pathways. *Hepatology* **61**, 1066-1079 (2015). https://doi.org:10.1002/hep.27332

27 Braunersreuther, V., Viviani, G. L., Mach, F. & Montecucco, F. Role of cytokines and chemokines in non-alcoholic fatty liver disease. *World J Gastroenterol* **18**, 727-735 (2012). https://doi.org:10.3748/wjg.v18.i8.727

28 De Juan, A. & Segura, E. Modulation of Immune Responses by Nutritional Ligands of Aryl Hydrocarbon Receptor. *Front Immunol* **12**, 645168 (2021). https://doi.org:10.3389/fimmu.2021.645168

29 Puri, P. *et al.* The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids. *Hepatology* **67**, 534-548 (2018). https://doi.org:10.1002/hep.29359

30 de Boer, J. F. *et al.* A human-like bile acid pool induced by deletion of hepatic Cyp2c70 modulates effects of FXR activation in mice. *J Lipid Res* **61**, 291-305 (2020). https://doi.org:10.1194/jlr.RA119000243

31 Ueda, H. *et al.* Sex-, age-, and organ-dependent improvement of bile acid hydrophobicity by ursodeoxycholic acid treatment: A study using a mouse model with human-like bile acid composition. *PLoS One* **17**, e0271308 (2022). https://doi.org:10.1371/journal.pone.0271308

32 Lobel, L., Cao, Y. G., Fenn, K., Glickman, J. N. & Garrett, W. S. Diet posttranslationally modifies the mouse gut microbial proteome to modulate renal function. *Science* **369**, 1518-1524 (2020). https://doi.org:10.1126/science.abb3763

33 Abu-Elheiga, L. *et al.* The subcellular localization of acetyl-CoA carboxylase 2. *Proc Natl Acad Sci U S A* **97**, 1444-1449 (2000). https://doi.org:10.1073/pnas.97.4.1444

34 Reddy, J. K. & Hashimoto, T. Peroxisomal beta-oxidation and peroxisome proliferator-activated receptor alpha: an adaptive metabolic system. *Annu Rev Nutr* **21**, 193-230 (2001). https://doi.org:10.1146/annurev.nutr.21.1.193

35 Enooku, K. *et al.* Altered serum acylcarnitine profile is associated with the status of nonalcoholic fatty liver disease (NAFLD) and NAFLD-related hepatocellular carcinoma. *Sci Rep* **9**, 10663 (2019). https://doi.org:10.1038/s41598-019-47216-2

36 Sunny, N. E., Parks, E. J., Browning, J. D. & Burgess, S. C. Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease. *Cell Metab* **14**, 804-810 (2011). https://doi.org:10.1016/j.cmet.2011.11.004

37 Dasarathy, S. *et al.* Elevated hepatic fatty acid oxidation, high plasma fibroblast growth factor 21, and fasting bile acids in nonalcoholic steatohepatitis. *Eur J Gastroenterol Hepatol* **23**, 382-388 (2011). https://doi.org:10.1097/MEG.0b013e328345c8c7

38 Miele, L. *et al.* Hepatic mitochondrial beta-oxidation in patients with nonalcoholic steatohepatitis assessed by 13C-octanoate breath test. *Am J Gastroenterol* **98**, 2335-2336 (2003). https://doi.org:10.1111/j.1572-0241.2003.07725.x

39 Petersen, K. F., Befroy, D. E., Dufour, S., Rothman, D. L. & Shulman, G. I. Assessment of Hepatic Mitochondrial Oxidation and Pyruvate Cycling in NAFLD by (13)C Magnetic Resonance Spectroscopy. *Cell Metab* **24**, 167-171 (2016). https://doi.org:10.1016/j.cmet.2016.06.005

40 Kotronen, A. *et al.* Liver fat and lipid oxidation in humans. *Liver Int* **29**, 1439-1446 (2009). https://doi.org:10.1111/j.1478-3231.2009.02076.x

41 Croci, I. *et al.* Whole-body substrate metabolism is associated with disease severity in patients with non-alcoholic fatty liver disease. *Gut* **62**, 1625-1633 (2013). https://doi.org:10.1136/gutjnl-2012-302789

42 von Loeffelholz, C. *et al.* Increased lipogenesis in spite of upregulated hepatic 5'AMP-activated protein kinase in human non-alcoholic fatty liver. *Hepatol Res* **47**, 890-901 (2017). https://doi.org:10.1111/hepr.12825

43 Palmieri, V. O., Grattagliano, I., Portincasa, P. & Palasciano, G. Systemic oxidative alterations are associated with visceral adiposity and liver steatosis in patients with metabolic syndrome. *J Nutr* **136**, 3022-3026 (2006). https://doi.org:10.1093/jn/136.12.3022

44 Del Ben, M. *et al.* Serum Cytokeratin-18 Is Associated with NOX2-Generated Oxidative Stress in Patients with Nonalcoholic Fatty Liver. *Int J Hepatol* **2014**, 784985 (2014). https://doi.org:10.1155/2014/784985

45 Del Ben, M. *et al.* NOX2-generated oxidative stress is associated with severity of ultrasound liver steatosis in patients with non-alcoholic fatty liver disease. *BMC Gastroenterol* **14**, 81 (2014). https://doi.org:10.1186/1471-230X-14-81

46 Jin, U. H. *et al.* Microbiome-derived tryptophan metabolites and their aryl hydrocarbon receptor-dependent agonist and antagonist activities. *Molecular pharmacology* **85**, 777-788 (2014). https://doi.org:10.1124/mol.113.091165

47 Datz, C., Muller, E. & Aigner, E. Iron overload and non-alcoholic fatty liver disease. *Minerva Endocrinol* **42**, 173-183 (2017). https://doi.org:10.23736/S0391-1977.16.02565-7

48 Vela, D. Low hepcidin in liver fibrosis and cirrhosis; a tale of progressive disorder and a case for a new biochemical marker. *Mol Med* **24**, 5 (2018). https://doi.org:10.1186/s10020-018-0008-7

49 Zhou, W. & Qiu, K. The correlation between lncRNA NEAT1 and serum hepcidin in the peripheral blood of non-alcoholic fatty liver disease patients. *Am J Transl Res* **14**, 2593-2599 (2022).

50 Senates, E. *et al.* Serum levels of hepcidin in patients with biopsy-proven nonalcoholic fatty liver disease. *Metab Syndr Relat Disord* **9**, 287-290 (2011). https://doi.org:10.1089/met.2010.0121

51 Mitsuyoshi, H. *et al.* Analysis of hepatic genes involved in the metabolism of fatty acids and iron in nonalcoholic fatty liver disease. *Hepatol Res* **39**, 366-373 (2009). https://doi.org:10.1111/j.1872-034X.2008.00464.x

52 Lu, S., Bennett, R. G., Kharbanda, K. K. & Harrison-Findik, D. D. Lack of hepcidin expression attenuates steatosis and causes fibrosis in the liver. *World J Hepatol* **8**, 211-225 (2016). https://doi.org:10.4254/wjh.v8.i4.211

53 Chen, H., Zhao, W., Yan, X., Huang, T. & Yang, A. Overexpression of Hepcidin Alleviates Steatohepatitis and Fibrosis in a Diet-induced Nonalcoholic Steatohepatitis. *J Clin Transl Hepatol* **10**, 577-588 (2022). https://doi.org:10.14218/JCTH.2021.00289

54 Li, Q., Harden, J. L., Anderson, C. D. & Egilmez, N. K. Tolerogenic Phenotype of IFN-gamma-Induced IDO+ Dendritic Cells Is Maintained via an Autocrine IDO-Kynurenine/AhR-IDO Loop. *Journal of immunology* **197**, 962-970 (2016). https://doi.org:10.4049/jimmunol.1502615

55 Wu, Y., Song, P., Xu, J., Zhang, M. & Zou, M. H. Activation of protein phosphatase 2A by palmitate inhibits AMP-activated protein kinase. *J Biol Chem* **282**, 9777-9788 (2007). https://doi.org:10.1074/jbc.M608310200

56 Ji, Y. *et al.* Anti-Inflammatory and Anti-Oxidative Activity of Indole-3-Acetic Acid Involves Induction of HO-1 and Neutralization of Free Radicals in RAW264.7 Cells. *International journal of molecular sciences* **21** (2020). https://doi.org:10.3390/ijms21051579

57 Zhang, C. *et al.* Indole-3-acetic acid improves the hepatic mitochondrial respiration defects by PGC1a up-regulation. *Cell Signal* **99**, 110442 (2022). https://doi.org:10.1016/j.cellsig.2022.110442

58 Ji, Y., Gao, Y., Chen, H., Yin, Y. & Zhang, W. Indole-3-Acetic Acid Alleviates Nonalcoholic Fatty Liver Disease in Mice via Attenuation of Hepatic Lipogenesis, and Oxidative and Inflammatory Stress. *Nutrients* **11** (2019). https://doi.org:10.3390/nu11092062

59 Kleiner, D. E. *et al.* Design and validation of a histological scoring system for nonalcoholic fatty liver disease. *Hepatology* **41**, 1313-1321 (2005). https://doi.org:10.1002/hep.20701

60 Bedossa, P. & Consortium, F. P. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. *Hepatology* **60**, 565-575 (2014). https://doi.org:10.1002/hep.27173

61 Kozich, J. J., Westcott, S. L., Baxter, N. T., Highlander, S. K. & Schloss, P. D. Development of a dual-index sequencing strategy and curation pipeline for analyzing amplicon sequence data on the MiSeq Illumina sequencing platform. *Appl Environ Microbiol* **79**, 5112-5120 (2013). https://doi.org:10.1128/AEM.01043-13

62 Quast, C. *et al.* The SILVA ribosomal RNA gene database project: improved data processing and web-based tools. *Nucleic Acids Res* **41**, D590-596 (2013). https://doi.org:10.1093/nar/gks1219

63 Segata, N. *et al.* Metagenomic biomarker discovery and explanation. *Genome Biol* **12**, R60 (2011). https://doi.org:10.1186/gb-2011-12-6-r60

64 Yang, F. *et al.* Effect of diet and intestinal AhR expression on fecal microbiome and metabolomic profiles. *Microb Cell Fact* **19**, 219 (2020). https://doi.org:10.1186/s12934-020-01463-5

65 Dettmer, K. *et al.* Metabolite extraction from adherently growing mammalian cells for metabolomics studies: optimization of harvesting and extraction protocols. *Anal Bioanal Chem* **399**, 1127-1139 (2011). https://doi.org:10.1007/s00216-010-4425-x

66 Manteiga, S. & Lee, K. Monoethylhexyl Phthalate Elicits an Inflammatory Response in Adipocytes Characterized by Alterations in Lipid and Cytokine Pathways. *Environ Health Perspect* **125**, 615-622 (2017). https://doi.org:10.1289/EHP464

67 Pang, Z. *et al.* Using MetaboAnalyst 5.0 for LC-HRMS spectra processing, multi-omics integration and covariate adjustment of global metabolomics data. *Nat Protoc* **17**, 1735-1761 (2022). https://doi.org:10.1038/s41596-022-00710-w

68 Anderson, M. J. in *Wiley StatsRef: Statistics Reference Online* 1-15.

**Acknowledgments:**

We gratefully acknowledge the use of facilities at the Microbial Analysis, Resources, and Services, (MARS) Center for Open Research Resources and Equipment at the University of Connecticut, Texas A&M High Performance Research Computing, Integrated Metabolomics Analysis Core (IMAC) at Texas A&M University, and Mass Spectrometry Core Lab at Tufts University.

**Funding:**

Ray B. Nesbitt Chair endowment, Texas A&M (AJ)
Karol Family Professorship (KL)

**Author contributions:**

Conceptualization: KL, AJ
Methodology: YD, KY, FY, EC, CC, MEH, RM, RCA
Investigation: YD, KY, FY, EC, CC, MEH, RM, KL, AJ
Visualization: YD, KY
Funding acquisition: KL, AJ
Project administration: KL, AJ
Supervision: RCA, KL, AJ
Writing – original draft: YD, KY, EC
Writing – review & editing: YD, KY, KL, AJ

**Competing interests:** Authors declare they have no competing interests

**Data and materials availability:** All data are available in the main text or Supplemental Information.




**Fig. 1. Oral administration of I3A alleviates diet induce hepatic steatosis and inflammation.** **(A)** Fecal (at weeks 8 and 16) and **(B)** liver (at week 16) concentrations of I3A in male B6 129SF1/J mice in control low-fat diet (CN), Western diet (WD), Western diet with low-dose I3A (WD-50), and Western diet with high-dose I3A (WD-100). (**C)** Serum alanine aminotransferase (ALT) levels in mice at weeks 10 and 16. **(D)** Liver triglyceride (TG) levels at week 16. Data shown are TG concentrations (mg/dl) normalized to corresponding tissue DNA contents (µg DNA). **(E)**

905 Representative liver sections stained with hematoxylin-eosin (H&E). **(F)** Histology score for
906 steatosis, hepatocyte ballooning and lobular inflammation. H&E-stained liver sections were
907 evaluated by an expert pathologist using the NASH CRN and fatty liver inhibition of progression
908 (FLIP) consortia criteria. Data shown are mean ± SEM (n = 10 per group). *: $p<0.05$, **: $p<0.01$,
909 ***: $p<0.001$ using Wilcoxon rank sum test.
910
911
912
913
914




**Fig. 2. I3A administration reverses WD induced alterations in liver inflammatory cytokines and bile acids. (A)** Inflammatory cytokines in liver tissue at week 16. **(B)** Liver total bile acid concentration (left panel), and abundance of CDCA branch bile acids relative to total bile acids pool (right panel). Data shown are mean ± SEM. *: $p<0.05$, **: $p<0.01$, ***: $p<0.001$ using Wilcoxon rank sum test.




**Fig. 3. I3A administration partially reverses diet-induced metabolome alterations in the liver. (A)** Scatter plots of latent variable projections from PLS-DA of untargeted metabolomics data features. Comparison of all four experimental groups (left panel), CN vs. WD group (middle panel), and WD vs. WD-50 and WD-100 groups (right panel). **(B)** Heatmap of significant metabolite features (FDR<0.05) based on statistical comparisons of treatment groups (CN vs. WD). (C) KEGG pathway enrichment analysis of the metabolites. Number in the parenthesis represents the metabolites detected in the pathway. (D) Schematic for tryptophan metabolism (left panel). Tryptophan metabolism metabolites fold changes of WD-50, WD-100, CN relative to WD

933 (right panel). (E) Acyl-Carnitine fold change of WD-50, WD-100, CN relative to WD. p-values
934 were calculated using Student *t*-test and corrected by FDR.
935
936
937
938
939
940
941
942
943
944
945




C

| KEGG pathway enriched in CN over WD | GeneRatio | BgRatio | pvalue |
|---|---|---|---|
| Lysosome | 4/22 | 19/454 | 9.95E-03 |
| **Biosynthesis of unsaturated fatty acids** | **2/22** | **5/454** | **2.05E-02** |
| Phagosome | 3/22 | 14/454 | 2.54E-02 |
| Autophagy - animal | 2/22 | 6/454 | 2.99E-02 |
| Hematopoietic cell lineage | 2/22 | 7/454 | 4.06E-02 |
| Tuberculosis | 2/22 | 7/454 | 4.06E-02 |

| KEGG pathway enriched in WD100 over WD | GeneRatio | BgRatio | pvalue |
|---|---|---|---|
| Cysteine and methionine metabolism | 7/52 | 11/454 | 4.05E-05 |
| Arginine and proline metabolism | 5/52 | 10/454 | 2.64E-03 |
| **Biosynthesis of unsaturated fatty acids** | 3/52 | 5/454 | 1.20E-02 |
| Steroid hormone biosynthesis | 4/52 | 10/454 | 1.91E-02 |
| Peroxisome | 6/52 | 21/454 | 2.37E-02 |

**Fig. 4. I3A administration partially reverses diet-induced proteome alterations in the liver.** **(A)** Scatter plots of latent variable projections from PLS-DA of confidently identified proteins. Comparison of all four experimental groups (left panel), CN vs WD group (middle panel), and WD vs. WD-50 and WD-100 groups (right panel). **(B)** Heatmap of significant proteins having Variable Importance in Projection score >1.2. The proteins were clustered using k-means. **(C)** Pathway enrichment analysis of significant proteins differentially abundant in CN vs. WD comparison (upper panel) and WD-100 vs. WD comparison (lower panel). GeneRatio divides the number of significantly altered proteins that are in the pathway by the total number of significantly altered proteins. BGRatio divides the number of proteins that are in the pathway by the number of all detected proteins. The *p*-value was calculated using Fisher's exact test.




958

959 **Fig. 5. I3A administration reduces the levels of enzymes in fatty acid transport, *de novo***

960 **lipogenesis and β-oxidation. (A)** Abundance of fatty acid translocase (CD36) and fatty acid

961 synthase. **(B)** Mitochondrial and **(C)** peroxisomal fatty acid oxidation enzymes. Data shown are

962 mean ± SEM. *: $p<0.05$, **: $p<0.01$ using Wilcoxon rank sum test

963

964




965

966 **Fig. 6. I3A suppresses macrophage inflammation *in vitro* in an AMPK dependent manner**.

967 **(A)** and **(B)** I3A administration reverses WD-induced reduction in liver p-AMPK and AMPK. **(A)**

968 Levels of p-AMPK and AMPK in liver tissue at week 16 as determined by Western blot analysis.

969 **(B)** Ratios of p-AMPK (left panel) and AMPK (right panel) to β-actin. The ratios were determined
970 based on the p-AMPK and AMPK band intensities quantified using Image Lab (Bio-Rad) and
971 normalized to the loading control (β-actin). Data shown are mean ± SEM. *: $p<0.05$, **: $p<0.01$
972 using Wilcoxon rank sum test. **(C)** Expression levels of p-AMPK and total AMPK in RAW 264.7
973 macrophages pre-treated with either I3A or vehicle (DMF) control followed by stimulation with
974 palmitate and LPS, determined by Western blot analysis. **(D)** Fold-changes in p-AMPK and total
975 AMPK. Fold-changes were calculated relative to the DMF and no palmitate and LPS stimulation
976 condition. The band intensities were quantified and normalized to loading control (β-actin) by
977 using Image Lab (Bio-Rad). **(E)** Expression levels of *tnfα* and *il-1β* in RAW 264.7 cells treated
978 with p-AMPK activator AICAR, followed by stimulation with palmitate and LPS. **(F)** Expression
979 levels of *tnf*α (top row) and *il-1β* (bottom row) in RAW 264.7 cells transduced with non-targeted
980 control siRNA (left panels) or *Prkaa1* siRNA (middle panels), pre-treated with I3A, and then
981 stimulated with palmitate and LPS. Data shown are mean ± SEM from three independent cultures
982 with three biological replicates. *: $p<0.05$, **: $p<0.01$, ***: $p<0.001$ using Student's *t*- test.
983
984
985

986 **SUPPLEMENTAL INFORMATION**

987

988

989 **Microbially-derived indole-3-acetate alleviates diet induced steatosis and inflammation in mice**

990 Yufang Ding[1], Karin Yanagi[2], Fang Yang[1], Evelyn Callaway[1], Clint Cheng[1], Martha E Hensel[3], Rani Menon[1], Robert

991 Alaniz[4], Kyongbum Lee[2*], Arul Jayaraman[1,4*]

992

993 [1]Artie McFerrin Department of Chemical Engineering, Texas A&M University, College Station, TX 77843, USA

994 [2]Department of Chemical and Biological Engineering, Tufts University, Medford, MA 02155, USA

995 [3]Department of Pathobiology, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University,

996 College Station, TX, USA

997 [4] Department of Microbial Pathogenesis and Immunology, College of Medicine, Texas Health Science Center, Texas

998 A&M University, Bryan, TX, USA

999

1000

1001

1002

1003

1004

1005

1006

1007

1008

1009

1010

1011

1012

1013

1014 **Material and methods**

1015 **Free fatty acid analysis**

1016 Free fatty acids (FFAs) in the liver and serum were quantified using product ion scan experiments (TripleTOF 5600+,
1017 AB Sciex, Framingham, MA). Chromatographic separation was achieved on a C18 column (Gemini 5 µm C18 110
1018 Å, LC Column 250 x 2 mm, 5µm, Phenomenex) using the solvent gradient described in Table S5. Solvent A was
1019 acetonitrile/water (3/2, v/v) containing 10 mM ammonium acetate. Solvent B was acetonitrile/isopropanol (1/1, v/v).
1020 The injection volume was 5 µL, and the oven temperature was set to 55°C. The flow rate was held at 1 mL/min. The
1021 mass spectrometer was operated in negative electrospray ionization (ESI-) mode with $MS^2$ scan. The experimental
1022 parameters are described in Table S2. "Light" experiments with low collision energy were used for quantification.
1023 "Heavy" experiments with high collision energy were used to confirm peak identity. The sample AUCs were converted
1024 into absolute concentrations using calibration curves from chemical standards. The FFA concentrations were then
1025 normalized by the corresponding sample DNA concentration.

1026

1027 **Untargeted proteomics**

1028 Proteins extracted from homogenized liver tissue samples were reduced at 37 °C for 30 min using a 50 mM
1029 dithiothreitol solution in 50 mM Tris-HCl containing 8 M urea. The reduced proteins were alkylated by incubating
1030 the sample in the dark for 15 min with 45.5 mM iodoacetamide. The reduced and alkylated proteins were digested
1031 using trypsin. After incubating the sample overnight at 37°C, formic acid was added to lower the pH to 2 and terminate
1032 the digest. The sample solution was centrifuged for 5 min at 14,000×g and desalted using spin columns (Pierce,
1033 Thermo Fisher). The desalting procedure followed the manufacturer's instruction except that 0.1% (v/v) formic acid
1034 was used instead of 0.1% (v/v) trifluoroacetic acid.

1035 Chromatographic separation was achieved on a reverse phase (RP) column (Ascentis Express C18, 2.7 µm
1036 100Å 15cm x 2.1 mm, Sigma) using a gradient method (Table S6). Solvent A was a 0.1% formic acid solution in
1037 water, and solvent B was a 0.1% formic acid solution in acetonitrile. The mobile phase flow rate was held constant at
1038 200 µL/min. The IDA method comprised a TOF MS (survey) scan and (triggered) high-resolution MS/MS (product
1039 ion) scans monitoring up to 25 candidate ions per cycle. The dependent scans were triggered whenever the survey
1040 scan detected a precursor ion matching the following criteria: mass range of 300-1250 m/z, charge state within +2 to
1041 +5, mass tolerance of 50 mDa, ion peak is not an isotope within 6 Da, and ion count exceeds 100 cps. Previously

1042 fragmented target ions were excluded for 15 sec to improve the variety of fragmented ions. Collision energy was set
1043 to 10 eV.

1044 Ions detected in the IDA experiment were annotated using ProteinPilot (v.5.0, AB Sciex) against mouse
1045 proteins in the SwissProt database (Figure S8, Step A). Here, an ion refers to a charged peptide comprising a sequence
1046 of amino acids with or without modifications. Ions annotated as the same peptide were collected into one record (Step
1047 B). For each record, the average chromatographic retention time (RT), RT variation (relative to average), median
1048 peptide confidence score was calculated from the associated ion data. The peptides collected into records were filtered
1049 using an automated procedure implemented as a script in MATLAB (R2019b, MathWorks, Natick, MA) based on the
1050 following criteria (Step C). For each peptide, average RT and accurate mass in the record were compared with the
1051 ions of every other peptide having a different predicted sequence and modification. If a match with another peptide
1052 ion was found within 0.1 m/z and 0.5 min, the peptide was excluded from quantification since the overlap decreases
1053 confidence in quantitation. All comparisons were performed with ions instead of records because the average RT of a
1054 record can be unreliable due to multiple elution of peptides belonging to the same record. The data were analyzed to
1055 ensure that a peptide belongs to only one protein, is detected more than once, i.e., at least two ions are included in one
1056 record, the median confidence score of a record is greater than 95%, and the maximal difference between RTs of
1057 peptide ions within a single record is less than 0.5 min.

1058 Peptides meeting the above criteria were analyzed in MultiQuant (v2.0, AB Sciex) to quantify the areas-
1059 under-the curve (AUCs) of corresponding extracted ion chromatograms (XICs) (Step D). The peptide AUCs were
1060 then normalized by the corresponding sample's sum of all peptide AUCs to control for sample-to-sample variability
1061 in total protein loaded onto the HPLC column (Step E). An additional filter was applied to exclude peptides that did
1062 not have AUCs above blank in at least 80% of the samples (Step F). Peptides with RTs that deviate more than 0.5 min
1063 among the samples were also excluded from further analysis. To select a representative peptide for protein
1064 quantification, peptides having post-translational modification sites were excluded, since the modified peptides can at
1065 most represent a fraction of the protein (Step G). If peptides having the same sequence and different charge states
1066 were identified for a protein, then the representative peptide was selected from this pool. Otherwise, the representative
1067 peptide was selected from all peptides belonging to the protein. In either case, the peptide with the largest average
1068 normalized AUC across all samples was selected to represent the corresponding protein's relative abundance.

1069

1070

1071

1072 Table S1. LC-MS parameters for bile acid analysis

1073

| Bile acid | RT (min) | Polarity | Precursor (m/z) | Product (m/z) | CE (V) | RF Lens (V) |
|---|---|---|---|---|---|---|
| Muricholic acid | 1.39 | Negative | 407.3 | 371.3 | 31.7 | 249 |
| Tauromuricholic acid | 0.9 | Negative | 514.5 | 79.9 | 55 | 185 |
| Tauro-β-muricholic acid | 1.87 | Negative | 514.5 | 80 | 55 | 248 |
| Taurohyodeoxycholic acid | 1.58 | Negative | 498.6 | 79.9 | 55 | 137 |
| Murideoxycholic acid | 2.54 | Negative | 391.5 | 327.3 | 34.3 | 170 |
| Glycocholic acid | 1.76 | Negative | 464.5 | 74 | 36.8 | 111 |
| Taurocholic acid | 1.87 | Negative | 514.5 | 79.9 | 55 | 137 |
| Ursodeoxycholic acid | 2.2 | Negative | 391.4 | 355.2 | 32.4 | 178 |
| Cholic acid | 2.64 | Negative | 407.8 | 290.3 | 37.5 | 131 |
| Hyodeoxycholic acid | 2.54 | Negative | 391.5 | 353.2 | 35.7 | 173 |
| Taurodeoxycholic acid | 3.05 | Negative | 498.4 | 79.9 | 54.6 | 198 |
| Deoxycholic acid | 4.83 | Negative | 391.4 | 327.2 | 34.6 | 146 |
| Chenodeoxycholic acid | 4.6 | Negative | 391.4 | 355.1 | 34.8 | 154 |

1074

1075 Table S2. LC-MS parameters for free fatty acid analysis

1076

| Free fatty acids | RT (min) | [M-H]- (m/z) | TOF $MS^2$ (m/z) | CE (V) | DE |
|---|---|---|---|---|---|
| Light Experiment for quantification | | | | | |
| Lauric acid | 1.94 | 199.17 | 199.17 | -8 | -100 |
| Myristic acid | 3.28 | 227.2 | 227.2 | -15 | -150 |
| Palmitic acid | 6.02 | 255.23 | 255.23 | -15 | -150 |
| Palmitoleic acid | 3.91 | 253.22 | 253.22 | -15 | -150 |
| Stearic acid | 10.81 | 283.26 | 283.26 | -15 | -150 |
| Oleic acid | 7.01 | 281.25 | 281.25 | -15 | -150 |
| Linoleic acid | 4.79 | 279.22 | 279.22 | -17 | -150 |
| Linolenic acid | 3.38 | 277.22 | 277.22 | -15 | -150 |
| Arachidonic acid | 4.57 | 303.23 | 303.23 | -10 | -175 |
| Heavy Experiment for confirmation | | | | | |
| Lauric acid | 1.94 | 199.17 | 199.17 | -21 | -100 |
| Myristic acid | 3.28 | 227.20 | 227.20 | -23 | -150 |
| Palmitic acid | 6.02 | 255.23 | 255.23 | -26 | -150 |
| Palmitoleic acid | 3.91 | 253.22 | 253.22 | -25 | -150 |
| Stearic acid | 10.81 | 283.26 | 283.26 | -25 | -150 |
| Oleic acid | 7.01 | 281.25 | 281.25 | -26 | -150 |
| Linoleic acid | 4.79 | 279.22 | 279.22 | -25 | -150 |
| Linolenic acid | 3.38 | 277.22 | 277.22 | -23 | -150 |
| Arachidonic acid | 4.57 | 303.23 | 303.23 | -20 | -175 |

1077

1078

1079 Table S3. Gradient method for untargeted metabolomics
1080

| Time (min) | % Solvent A | % Solvent B |
|---|---|---|
| 0 | 90 | 10 |
| 5 | 60 | 40 |
| 7 | 5 | 95 |
| 9 | 5 | 95 |
| 9.1 | 90 | 10 |
| 13 | 90 | 10 |

1081
1082 Solvent A: 0.1% (v/v) formic acid solution in water. Solvent B was a 0.1% (v/v) formic acid solution in methanol.
1083 The flow rate was 0.4 mL/min.
1084
1085
1086 Table S4. Gradient method for bile acid analysis
1087

| Time (min) | % Solvent A | % Solvent B |
|---|---|---|
| 0 | 55 | 45 |
| 9 | 30 | 70 |
| 9.5 | 30 | 70 |
| 9.51 | 55 | 45 |
| 12 | 60 | 40 |

1088
1089 Solvent A: 2 mM ammonium acetate in water. Solvent B: methanol:acetonitrile (50:50, V:V). The flow rate was 0.4
1090 mL/min.
1091
1092
1093 Table S5. Gradient method for free fatty acid analysis
1094

| Time (min) | % Solvent A | % Solvent B |
|---|---|---|
| 0 | 90 | 10 |
| 1.7 | 90 | 10 |
| 11.9 | 65 | 35 |
| 14.9 | 0 | 100 |
| 17.4 | 0 | 100 |
| 17.9 | 90 | 10 |
| 20 | 90 | 10 |

1095
1096
1097 Table S6. Gradient method for untargeted proteomics
1098

| Time (min) | % Solvent A | % Solvent B |
|---|---|---|
| 0 | 98 | 2 |
| 15 | 98 | 2 |
| 50 | 55 | 45 |
| 60 | 55 | 45 |
| 62 | 5 | 95 |
| 75 | 5 | 95 |
| 75.5 | 98 | 2 |
| 80 | 98 | 2 |

1099 Table S7. LC-MS parameters for targeted proteomics
1100

| Protein | Selected Peptide | CE (V) | m/z | Charge | RT (min) | Product ion(s) |
|---|---|---|---|---|---|---|

| | | | | | | |
|---|---|---|---|---|---|---|
| CD36 | VAIIESYK | 21.6 | 461.8 | 2 | 32.8 | 752.4 |
| Acox1 | TSNHAIVLAQLITR | 22.6 | 513 | 3 | 37.8 | 701.4 |
| Acaa1a | NTTPDELLSAVLTAVLQDVR | 32.5 | 719.1 | 3 | 53.3 | Sum of 901.5, 1014.6, 1113.7, 800.5, 729.4, 630.4, 517,3 |
| Acaa1b | DTTPDELLSAVLTAVLQDVK | 32.1 | 710.1 | 3 | 54.2 | 873.5 |
| Acads | IGIASQALGIAQASLDCAVK_Carbamidomethyl(C)@17 | 29.8 | 662.7 | 3 | 42.8 | 792.4 |
| Acadm | LLVEHQGVSFLLAEMAMK | 30.3 | 672.7 | 3 | 42.6 | 793.4 |
| Acadl | SPAHGISLFLVENGMK | 25.2 | 567.3 | 3 | 39 | 677.3 |
| Hadh | LLVPYLIEAVR | 30.5 | 643.4 | 2 | 43.1 | 960.6 |
| Acaa2 | TNVSGGAIALGHPLGGSGSR | 27 | 603.3 | 3 | 33.5 | 747.4 |
| Fasn | VLEALLPLK | 23.4 | 498.3 | 2 | 39.7 | 783.5 |
| Acab | VEANLLSSEESLSASELSGEQLQEHGDHSCLSYR_Carbamidomethyl(C)@30 | 45.1 | 941.2 | 4 | 38.1 | 1001.9 |
| Cat | GAGAFGYFEVTHDITR | 25.9 | 580.9 | 3 | 38.1 | 742.7 |
| Gpx1 | YVRPGGGFEPNFTLFEK | 29.4 | 653.3 | 3 | 39.5 | 498.3 |
| Hamp | DTNFPICIFCCK_Carbamidomethyl(C)@7; Carbamidomethyl(C)@10; Carbamidomethyl(C)@11 | 37.6 | 787.8 | 2 | 41.6 | 1097.5 |
| Tf | SAGWVIPIGLLFCK_Carbamidomethyl(C)@13 | 37.3 | 780.9 | 2 | 47 | 947.5 |

CD36: platelet glycoprotein 4; Acox1: peroxisomal acyl-coenzyme A oxidase 1; Acaa1a: peroxisomal 3-ketoacyl-CoA thiolase A; Acaa1b: peroxisomal 3-ketoacyl-CoA thiolase B; Acads: short-chain acyl-CoA dehydrogenase; Acadm: medium-chain acyl-CoA dehydrogenase; Acadl: long-chain acyl-CoA dehydrogenase; Hadh: hydroxyacyl-CoA dehydrogenase; Acaa2: mitochondrial 3-ketoacyl-CoA thiolase; Acab: acetyl-CoA carboxylase 2; Cat: catalase; Gpx1: Glutathione peroxidase 1; Hamp: hepcidin; Tf: serotransferrin

Table S8. Primer sequences

| **Gene** | **Forward Primer Sequence** | **Reverse Primer Sequence** |
|---|---|---|
| TNFα | TCTCATGCACCACCATCAAGGACT | TGACCACTCTCCCTTTGCAGAACT |
| IL-1β | TCCAGGATGAGGACATGAGCAC | GAACGTCACACACCAGCAGGTTA |
| β-actin | GGCTGTATTCCCCTCCATCG | CCAGTTGGTAACAATGCCATGT |

1113




1114

1115 **Fig. S1. Study design**. **(A)** Three groups of male B6 129SF1/J mice (n=10 for each group) were fed *ad libitum* a

1116 Western diet (WD) and a sugar water (SW) solution while a fourth group was given normal chow diet. After 8 weeks,

1117 the three groups of WD-fed mice were randomly selected for treatment with vehicle (WD group) or low (WD-50

1118 group) or high dose (WD-100 group) of I3A for an additional 8 weeks. The fourth group (CN) was continued on low-

1119 fat diet calorie matched with the WD. **(B)** Sampling scheme. **(C)** Quantification of I3A in serum. **(D)** Body weight
1120 increase and food intake of the four groups. Body weights were normalized to week 8 body weight when I3A
1121 administration was started. Food intakes were measured per cage and average food intake was calculated as per gram
1122 food intake per mouse per day. Data shown are mean ± SEM. *: $p<0.05$, **: $p<0.01$, WD group compared to CN
1123 group using Wilcoxon rank sum test.
1124
1125
1126
1127
1128




**Fig. S2. I3A reduces liver inflammatory cytokine expression and total FFA concentration. (A)** Inflammatory cytokines in liver tissue at week 16. **(B)** FFAs in diet, serum and liver samples. Data shown are mean ± SEM. *: $p<0.05$, **: $p<0.01$, ***: $p<0.001$ using Wilcoxon rank sum test.




**Fig. S3. I3A administration does not significantly alter the fecal microbial community**. **(A)** Alpha diversity of the fecal microbiome from CN, WD, WD-50, and WD-100 groups. **(B)** Analysis of Similarities (ANOSIM) comparison for CN vs. WD group and WD vs. WD-50 vs. WD-100 groups. **(C)** Phylum and **(D)** genus level relative abundance of the fecal microbial community members. **(E)** LEfSe results at the genus level. *: $p<0.05$, ***: $p<0.001$ using Wilcoxon rank sum test.




**Fig. S4. I3A administration does not significantly alter the fecal metabolome. (A)** Score plots show the first two principal components for all four experimental groups (left panel), CN vs. WD group (middle panel), and WD vs. WD-50 and WD-100 groups (right panel). Numbers in the parentheses of axis titles show percent of variance explained by the corresponding principal component. Ellipses circumscribe 95% confidence regions for the experimental groups assuming Gaussian distribution of component scores. **(B)** Heatmap of fecal microbiome metabolite features detected in all treatment groups. Rows and columns are features and treatment groups, respectively. The features were clustered using k-means.




**Fig. S5. Principal Component Analysis of liver proteome after I3A administration. (A)** Score plots of the first two principal components for all four experimental groups (left panel), CN vs. WD group (middle panel), and WD vs. WD-50 and WD-100 groups (right panel). Numbers in the parentheses of axis titles show percent of variance explained by the corresponding principal component. Ellipses represent 95% confidence regions for the experimental groups assuming Gaussian distribution of component scores.




1156

1157 **Fig. S6. I3A administration reduces the levels of antioxidant enzymes and affects iron metabolism related**

1158 **proteins. (A)** Catalase and glutathione peroxidase-1 abundance for the four experimental groups. **(B)** Hepcidin and

1159 Serotransferrin abundance. Data shown are mean ± SEM. *: $p<0.05$, **: $p<0.01$ using Wilcoxon rank sum test.




1160

1161 **Fig. S7. I3A's anti-inflammatory effects in macrophages are independent of AhR activation.** A. Expression

1162 level of AhR in RAW264.7 and AML12 cells determined by Western blot analysis. B. Raw 264.7 cells were treated

1163 with 1mM I3A (or DMF solvent control) for 4h, then stimulated with 300μM Palmitate for 18h and 10ng/ml LPS for

1164 6h (two-hits model). The AhR inhibitor CH223191 (5μM) or DMSO control were added 10min before I3A

1165 treatment. Total RNA were isolated from the cells and the expression of *tnfα* and *il-1β* were measured with qRT-

1166 PCR. C. *tnfα* and *il-1β* expression were plotted as fold change normalized to the DMF control group. Data presented

1167 as the mean ± SEM. ***: $p<0.001$ using Student's *t*-test.

1168




**Fig. S8. Prkaa1 siRNA reduces AMPK expression in macrophages. (A)** Levels of prkaa1 mRNA in RAW 264.7 cells transfected with prkaa1 or non-targeted control siRNA for 24 h, followed by incubation for an additional 24, 48, and 72 h. The expression level of prkaa1 is normalized to that of the housekeeping gene β-actin. **(B)** Western blot analysis of p-AMPK and total AMPK from cells treated with the different siRNA. A representative blot is shown. **(C)** Quantified intensities of p-AMPK and total AMPK bands normalized to loading control (β-actin).




**Fig. S9. Proposed model for the effects of I3A on hepatic lipid metabolism and inflammation.** When mice are fed with a WD (top panel), TG and FFAs accumulate in the liver due to increased uptake of fatty acids. This also leads to increased β-oxidation in the mitochondria and peroxisomes. In liver macrophages, the increase in FFAs, possibly in conjunction with circulating endotoxins (e.g., LPS) stimulate production of inflammatory cytokines. When mice fed the WD are treated with I3A (bottom panel), both TG and FFAs decrease in the liver. Rather than impact fatty acid uptake, I3A treatment reduces *de novo* lipogenesis through a downregulation of Fasn, while also reducing both

1183 mitochondrial and peroxisomal β-oxidation. In macrophages, I3A attenuates fatty acid and LPS stimulated production

1184 of inflammatory cytokines through activation of AMPK.

1185

1186




1187

1188 **Fig. S10. Untargeted proteomic data analysis workflow.** The individual steps (A - G) are described in the untargeted

1189 proteomics section of Supplemental Information.

1190

1191